Overview

A Study of the Safety and Levodopa Pharmacokinetics Following Single Dose Administration of CVT 301 (Levodopa Inhalation Powder) in Smoking and Non-Smoking Adults

Status:
Completed

Trial end date:
2016-06-01

Target enrollment:

Participant gender:

Summary

This is an open label, parallel group study to evaluate the pharmacokinetics (PK) and safety of a single dose of CVT-301 in smoking and non-smoking adults.

Phase:

Phase 1

Details

Lead Sponsor:

Acorda Therapeutics

Treatments:

Carbidopa
Levodopa